...
首页> 外文期刊>Human Pathology >A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer
【24h】

A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer

机译:4微克签名预测乳腺癌的淋巴结转移和预后

获取原文
获取原文并翻译 | 示例
           

摘要

Recent findings have reported that human microRNAs (miRNAs) could serve as prognostic biomarkers in various cancers. We aimed to identify miRNAs that were associated with lymph node metastasis (LNM) and prognosis in breast cancer patients. A miRNA microarray covering 2019 mature miRNAs was used to identify differentially expressed miRNAs in 9 patients with LNM and 3 patients without LNM. Thirty-five differentially expressed miRNAs were identified, of which 10 significantly were up-regulated, whereas the other 25 were down-regulated in tissues with LNM compared with those without LNM. Seven miRNAs were subjected to quantitative real-time polymerase chain PCR (qRT‐PCR) reaction, and 4 miRNAs (miR-191-5p, miR-214-3p, miR-451a, and miR-489) were validated in a total of 159 patients including a training set (n = 64) and a validation set (n = 95). The 4 miRNAs were used to construct a miRNA signature by logistic regression. Risk scores derived from the 4-miRNA signature were calculated to stratify the patients into high- or low-risk groups. Patients with high-risk scores had poorer overall survival and disease-free survival than did those with low-risk scores. The miRNA signature was an independent prognostic factor. MiR-191-5p increased, whereas miR-214-3p, miR-451a, and miR-489 inhibited cell proliferation, migration, and invasion abilities. The 4-miRNA signature may be a reliable prognostic and predictive tool for metastasis and survival in breast cancer patients.
机译:最近的发现报道称,人类微小RNA(miRNA)可以作为各种癌症的预后生物标志物。我们旨在鉴定与淋巴结转移(LNM)相关的miRNA,乳腺癌患者的预后。 MiRNA微阵列覆盖2019年成熟miRNA用于鉴定9例LNM和3名没有LNM患者的差异表达的miRNA。鉴定了三十五个差异表达的miRNA,其中10分钟显着调节,而其他25在与没有LNM的那些与LNM的组织中下调。对七种miRNA进行定量实时聚合酶链PCR(QRT-PCR)反应,并在总共验证4 miRNA(miR-191-5p,miR-214-3p,miR-451a和miR-489) 159名患者包括训练集(n = 64)和验证集(n = 95)。使用4 miRNA通过Logistic回归来构建miRNA签名。计算源自4- miRNA签名的风险评分以将患者分解为高或低风险群体。高风险评分的患者的整体生存较差和无病的生存,而不是具有低风险评分的人。 miRNA签名是一个独立的预后因素。 miR-191-5p增加,而miR-214-3p,miR-451a和miR-489抑制细胞增殖,迁移和侵袭能力。 4- miRNA签名可能是乳腺癌患者转移和生存的可靠预测和预测工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号